Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas

被引：41

作者：

Conde, Esther ^{[1
,2
]}

Hernandez, Susana ^{[1
]}

Prieto, Mario ^{[1
,2
]}

Martinez, Rebeca ^{[1
]}

Lopez-Rios, Fernando ^{[1
,2
]}

机构：

[1] Hosp Univ HM Sanchinarro, Lab Dianas Terapeut, Madrid, Spain

[2] Univ San Pablo CEU, Fac Med, Madrid, Spain

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 06期

关键词：

ALK; lung carcinoma; FISH; IHC; companion diagnostic; ANAPLASTIC LYMPHOMA KINASE; CANCER PATIENTS; SCREENING TOOL; FUSION GENE; IMMUNOHISTOCHEMISTRY; REARRANGEMENT; FISH; CRIZOTINIB; ADENOCARCINOMA; IDENTIFICATION;

D O I：

10.1586/14737159.2016.1172963

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The development of several ALK inhibitors means that the importance of accurately identifying ALK-positive lung cancer has never been greater. Therefore, it is crucial that ALK testing assays become more standardized. The aim of this review is to comment on the recently FDA-approved VENTANA ALK (D5F3) Companion Diagnostic (CDx) Assay. This kit provides high sensitivity and specificity for the detection of ALK rearrangements and seamless integration into the laboratory workflow, with a fully automated analytical phase and fast interpretation. The use of controls increases the sensitivity and specificity and a dichotomous scoring approach enhances reproducibility.

引用

页码：707 / 713

页数：7

共 39 条

[1]

[Anonymous], 2015, NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis

[2]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[3] Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers [J].

Conde, E. ;

Angulo, B. ;

Izquierdo, E. ;

Paz-Ares, L. ;

Belda-Iniesta, C. ;

Hidalgo, M. ;

Lopez-Rios, F. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (07) :503-508

[4] The anaplastic lymphoma kinase testing conundrum [J].

Conde, Esther ;

Taniere, Philippe ;

Lopez-Rios, Fernando .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (02) :161-163

[5] Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry [J].

Conde, Esther ;

Suarez-Gauthier, Ana ;

Benito, Amparo ;

Garrido, Pilar ;

Garcia-Campelo, Rosario ;

Biscuola, Michele ;

Paz-Ares, Luis ;

Hardisson, David ;

de Castro, Javier ;

Camacho, M. Carmen ;

Rodriguez-Abreu, Delvys ;

Abdulkader, Ihab ;

Ramirez, Josep ;

Reguart, Noemi ;

Salido, Marta ;

Pijuan, Lara ;

Arriola, Edurne ;

Sanz, Julian ;

Folgueras, Victoria ;

Villanueva, Noemi ;

Gomez-Roman, Javier ;

Hidalgo, Manuel ;

Lopez-Rios, Fernando .

PLOS ONE, 2014, 9 (09)

[6] The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre [J].

Conde, Esther ;

Angulo, Barbara ;

Izquierdo, Elisa ;

Munoz, Luna ;

Suarez-Gauthier, Ana ;

Plaza, Carlos ;

Dominguez, Nuria ;

Torres, Maribel ;

Madrigal, Luis ;

Rubio-Viqueira, Belen ;

Belda-Iniesta, Cristobal ;

Hidalgo, Manuel ;

Lopez-Rios, Fernando .

HISTOPATHOLOGY, 2013, 62 (04) :609-616

[7] Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent [J].

Conklin, Chris M. J. ;

Craddock, Kenneth J. ;

Have, Cherry ;

Laskin, Janessa ;

Couture, Christian ;

Ionescu, Diana N. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) :45-51

[8] Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology [J].

Felip, E. ;

Concha, A. ;

de Castro, J. ;

Gomez-Roman, J. ;

Garrido, P. ;

Ramirez, J. ;

Isla, D. ;

Sanz, J. ;

Paz-Ares, L. ;

Lopez-Rios, F. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) :103-112

[9] Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib [J].

Gainor, Justin F. ;

Sherman, Carol A. ;

Willoughby, Kathryn ;

Logan, Jennifer ;

Kennedy, Elizabeth ;

Brastianos, Priscilla K. ;

Chi, Andrew S. ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) :232-236

[10] Clinical Implications of Variant ALK FISH Rearrangement Patterns [J].

Gao, Xin ;

Sholl, Lynette M. ;

Nishino, Mizuki ;

Heng, Jennifer C. ;

Jaenne, Pasi A. ;

Oxnard, Geoffrey R. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) :1648-1652

← 1 2 3 4 →